Apellis Pharmaceuticals (APLS) Scheduled to Post Quarterly Earnings on Tuesday

Apellis Pharmaceuticals (NASDAQ:APLS) is set to post its quarterly earnings results before the market opens on Tuesday, May 7th. Analysts expect Apellis Pharmaceuticals to post earnings of ($0.55) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings data on Tuesday, February 27th. The company reported ($0.73) EPS for the quarter, hitting analysts’ consensus estimates of ($0.73). The firm had revenue of $146.38 million during the quarter, compared to analyst estimates of $143.34 million. Apellis Pharmaceuticals had a negative return on equity of 178.60% and a negative net margin of 133.34%. The company’s revenue for the quarter was up 545.9% on a year-over-year basis. During the same period in the previous year, the company posted ($1.50) EPS. On average, analysts expect Apellis Pharmaceuticals to post $-1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Apellis Pharmaceuticals Stock Down 0.1 %

Shares of NASDAQ:APLS opened at $47.46 on Monday. The business’s 50 day moving average is $55.71 and its 200 day moving average is $57.53. Apellis Pharmaceuticals has a 12-month low of $19.83 and a 12-month high of $94.75. The stock has a market cap of $5.76 billion, a price-to-earnings ratio of -10.59 and a beta of 0.97. The company has a quick ratio of 2.50, a current ratio of 3.10 and a debt-to-equity ratio of 0.48.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on APLS. Jefferies Financial Group upgraded shares of Apellis Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their target price for the company from $68.00 to $80.00 in a research note on Monday, February 5th. The Goldman Sachs Group raised their target price on Apellis Pharmaceuticals from $65.00 to $90.00 and gave the stock a “buy” rating in a research report on Tuesday, January 9th. Needham & Company LLC reaffirmed a “buy” rating and set a $85.00 price target on shares of Apellis Pharmaceuticals in a research report on Thursday, April 25th. Wedbush decreased their price objective on Apellis Pharmaceuticals from $67.00 to $57.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $92.00 price objective on shares of Apellis Pharmaceuticals in a report on Friday, April 26th. Three equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Apellis Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $77.40.

Insider Buying and Selling at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, insider Adam J. Townsend sold 1,148 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $67.77, for a total transaction of $77,799.96. Following the completion of the transaction, the insider now owns 92,453 shares of the company’s stock, valued at approximately $6,265,539.81. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CFO Timothy Eugene Sullivan sold 1,431 shares of Apellis Pharmaceuticals stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $67.77, for a total transaction of $96,978.87. Following the completion of the transaction, the chief financial officer now directly owns 93,338 shares of the company’s stock, valued at approximately $6,325,516.26. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Adam J. Townsend sold 1,148 shares of the company’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $67.77, for a total transaction of $77,799.96. Following the completion of the sale, the insider now owns 92,453 shares in the company, valued at approximately $6,265,539.81. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 376,427 shares of company stock worth $23,169,639. 7.50% of the stock is currently owned by company insiders.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).